NEW YORK CITY, NY / ACCESS Newswire / November 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alvotech ("Alvotech" or "the Company") (NASDAQ:ALVO). Investors who purchased Alvotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ALVO.
Investigation Details
On November 2, 2025, Alvotech issued a press release "announcing . . . that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab)." According to the press release, "[t]he CRL noted that certain deficiencies, which were conveyed following the FDA’s pre-license inspection of Alvotech’s Reykjavik manufacturing facility that concluded in July 2025, must be satisfactorily resolved before this BLA for AVT05 can be approved." Following this news, Alvotech stock dropped $2.62 per share, or 34.25%, to close at $5.03 on November 3, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Alvotech securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ALVO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_470054493/2457/2025-11-05T17:14:22